• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 8-K filed by Merus N.V.

    5/8/24 8:01:01 AM ET
    $MRUS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $MRUS alert in real time by email
    8-K
    P7 00-0000000 016 2500 NL false 0001651311 0001651311 2024-05-07 2024-05-07

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM 8-K

     

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d)

    of the Securities Exchange Act of 1934

    Date of report (Date of earliest event reported): May 7, 2024

     

     

    MERUS N.V.

    (Exact name of registrant as specified in its charter)

     

     

     

    The Netherlands   001-37773   Not Applicable

    (State or other jurisdiction of

    incorporation or organization)

     

    (Commission

    File Number)

     

    (I.R.S. Employer

    Identification No.)

    Uppsalalaan 17

    3584 CT Utrecht

    The Netherlands

    (Address of principal executive offices) (Zip Code)

    +31 85 016 2500

    (Registrant’s telephone number, including area code)

    N/A

    (Former Name or Former Address, if Changed Since Last Report)

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act

     

    Title of each class

     

    Trading

    Symbol(s)

     

    Name of each exchange

    on which registered

    Common Shares, €0.09 nominal value per share   MRUS   The Nasdaq Global Market

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter)

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     


    Item 5.02

    Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

    On May 7, 2024, Merus N.V. (the “Company”) held its annual general meeting of shareholders (the “Annual Meeting”).

    At the Annual Meeting, the shareholders of the Company approved the amendment and restatement of the Merus N.V. 2016 Incentive Award Plan (the “Existing Plan” and, as amended and restated, the “A&R 2016 Plan”) to effect certain changes to the Existing Plan, including to: (i) extend the term of the Existing Plan to December 31, 2031 and (ii) extend the annual “evergreen” feature from and including January 1, 2026 to January 1, 2029. The A&R 2016 Plan was previously approved, subject to shareholder approval, by the Board. The A&R 2016 Plan amends and restates the Existing Plan in its entirety.

    The material terms and conditions of the A&R 2016 Plan are described under “Proposal 12: Approval of the amendment and restatement of the Company’s 2016 Incentive Award Plan (the “2016 Plan”) to extend the term of the 2016 Plan to December 31, 2031, which includes a corresponding extension to the annual “evergreen” feature from and including January 1, 2026 to January 1, 2029, along with other minor amendments updated for best practices” included in the Company’s definitive proxy statement on Schedule 14A filed with the Securities and Exchange Commission (the “SEC”) on April 10, 2024, as amended and supplemented by that certain proxy statement supplement filed by the Company with the SEC on April 11, 2024 (together, the “Definitive Proxy Statement”), which description is incorporated herein by reference.

    The above and the incorporated description of the A&R 2016 Plan are qualified in their entirety by reference to the A&R 2016 Plan, a copy of which is filed as an exhibit to the Definitive Proxy Statement.

     

    Item 5.07

    Submission of Matters to a Vote of Security Holders.

    On May 7, 2024, the Company held its Annual Meeting. For all proposals, a total of 48,249,183 common shares were present or represented by proxy at the Annual Meeting, representing approximately 82.21% of the Company’s outstanding common shares as of the April 9, 2024 record date.

    The following are the voting results for the proposals considered and voted upon at the Annual Meeting, all of which were described in the Definitive Proxy Statement.

    Proposal 1 - Adoption of Dutch statutory annual accounts for the financial year 2023:

     

    For

     

    Against

     

    Abstain

     

    Broker Non-Votes

    42,289,656   348   1,053   5,958,126

    Proposal 2 - Appointment of KPMG Accountants N.V. as the Company’s external auditor for the financial year 2024 for purposes of Dutch law:

     

    For

     

    Against

     

    Abstain

     

    Broker Non-Votes

    48,130,696   111,313   50077,174   0

    Proposal 3 - Release of each member of our board of directors from liability for the exercise of their duties during the financial year 2023:

     

    For

     

    Against

     

    Abstain

     

    Broker Non-Votes

    41,898,799   390,484   1,774   5,958,126

    Proposal 4 - Re-appointment of Mark Iwicki as non-executive director:

     

    For

     

    Against

     

    Abstain

     

    Broker Non-Votes

    29,335,264   12,955,514   279   5,958,126

    Proposal 5 - Re-appointment of Paolo Pucci as non-executive director:

     

    For

     

    Against

     

    Abstain

     

    Broker Non-Votes

    42,022,158   268,820   79   5,958,126

    Proposal 6 - Appointment of Jason Haddock as non-executive director:

     

    For

     

    Against

     

    Abstain

     

    Broker Non-Votes

    42,283,426   7,552   79   5,958,126

    Proposal 7 - Articles Amendment A – Approval of the amendment of the Articles of Association to increase the authorized share capital to the amount of EUR 18,900,000 and divided into 105,000,000 common shares and 105,000,000 preferred shares and authorization to implement such amendment:

     

    For

     

    Against

     

    Abstain

     

    Broker Non-Votes

    33,072,268   9,218,543   246   5,958,126


    Proposal 8 – Articles Amendment B - Approval of the amendment of the Articles of Association to reflect Large Company Regime and authorization to implement such amendment

     

    For

     

    Against

     

    Abstain

     

    Broker Non-Votes

    32,042,967   10,247,269   821   5,958,126

    Proposal 9 - Granting authorization to the Company’s board of directors to acquire shares (or depository receipts for such shares) in the Company’s capital:

     

    For

     

    Against

     

    Abstain

     

    Broker Non-Votes

    42,286,864   2,338   1,855   5,958,126

    Proposal 10 - Approval, on an advisory (non-binding) basis, of the compensation of our named executive officers:

     

    For

     

    Against

     

    Abstain

     

    Broker Non-Votes

    42,134,653   154,934   1,470   5,958,126

    Proposal 11 - Approval of the amendment of the Company’s Non-Executive Director Compensation Program (“NED Program”) to allow the board of directors to determine the number of common shares that may be awarded to a non-executive director for initial and annual awards under the NED Program to more closely align with the 50th percentile of the Company’s peer group:

     

    For

     

    Against

     

    Abstain

     

    Broker Non-Votes

    31,988,309   10,301,272   1,476   5,958,126

    Proposal 12 - Approval of the amendment and restatement of the Company’s 2016 Incentive Award Plan (the “2016 Plan”), to extend the term of the 2016 Plan to December 31, 2031, which includes a corresponding extension to the annual “evergreen” feature from and including January 1, 2026 to January 1, 2029, along with other minor amendments updated for best practices:

     

    For

     

    Against

     

    Abstain

     

    Broker Non-Votes

    27,369,938   14,920,150   969   5,958,126

    Based on the foregoing votes, the shareholders re-elected Mark Iwicki as a executive director to serve until the 2026 annual general meeting, re-elected Paolo Pucci as non-executive director to serve until the 2028 annual general meeting and elected Jason Haddock as non-executive director to serve until the 2028 annual general meeting, and approved Proposals 1, 2, 3, 7, 8, 9, 10, 11 and 12.


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

        MERUS N.V.
    Date: May 8, 2024     By:  

    /s/ Sven A. Lundberg

        Name:   Sven (Bill) Ante Lundberg, M.D.
        Title:   President, Chief Executive Officer
    Get the next $MRUS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MRUS

    DatePrice TargetRatingAnalyst
    9/17/2025$112.00Overweight
    Barclays
    8/25/2025$90.00Buy
    Alliance Global Partners
    2/13/2025$84.00Overweight
    Piper Sandler
    2/7/2025$91.00Overweight
    Wells Fargo
    11/21/2024$73.00Buy
    Goldman
    10/24/2024$72.00Buy
    UBS
    3/28/2024$69.00Buy
    Truist
    3/4/2024$42.00 → $65.00Buy
    Needham
    More analyst ratings

    $MRUS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Immunotherapy Breakthroughs Turn Cold GI Tumors Hot as Market Tops $443B

    Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, Dec. 16, 2025 /PRNewswire/ -- USANewsGroup.com News Commentary – Gastrointestinal cancers that once resisted checkpoint inhibitors are finally responding to novel combination strategies[1], with the FDA fast-tracking multiple targeted therapies designed to transform immunologically cold tumors into treatment-responsive hot targets[2]. This pivotal shift positions Oncolytics Biotech Inc. (NASDAQ:ONCY), AIM ImmunoTech (NYSE-American: AIM), ArriVent BioPharma, Inc. (NASDAQ:AVBP), Merus N.V. (NASDAQ:MRUS), and Halozyme Therapeutics, Inc. (NASDAQ:HALO) as potential leaders in the battle against stolid tumors, including gastrointestinal ca

    12/16/25 1:17:00 PM ET
    $AIM
    $AVBP
    $HALO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Genmab Announces Completion of Tender Offer for Outstanding Common Shares of Merus N.V. and Commencement of Subsequent Offering Period

    Company Announcement Transaction adds petosemtamab, a late-stage asset with two Breakthrough Therapy Designations, to Genmab's portfolio Transaction anticipated to be accretive to Genmab's EBITDA by end of 2029   Genmab A/S (NASDAQ:GMAB) ("Genmab") announced today that the conditions, including the minimum tender condition, to the previously announced tender offer (the "Offer") by Genmab Holding II B.V., a wholly owned subsidiary of Genmab ("Purchaser"), to acquire all the issued and outstanding common shares of Merus N.V. (NASDAQ:MRUS) ("Merus") for $97 per common share in cash have been satisfied. The transaction meaningfully accelerates Genmab's shift to a wholly owned model, expa

    12/12/25 1:36:00 AM ET
    $GMAB
    $MRUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Genmab Announces Completion of Tender Offer for Outstanding Common Shares of Merus N.V. and Commencement of Subsequent Offering Period

    Company Announcement Transaction adds petosemtamab, a late-stage asset with two Breakthrough Therapy Designations, to Genmab's portfolioTransaction anticipated to be accretive to Genmab's EBITDA by end of 2029 COPENHAGEN, Denmark; December 12, 2025 – Genmab A/S (NASDAQ:GMAB) ("Genmab") announced today that the conditions, including the minimum tender condition, to the previously announced tender offer (the "Offer") by Genmab Holding II B.V., a wholly owned subsidiary of Genmab ("Purchaser"), to acquire all the issued and outstanding common shares of Merus N.V. (NASDAQ:MRUS) ("Merus") for $97 per common share in cash have been satisfied. The transaction meaningfully accelerates Genmab's shi

    12/12/25 1:35:27 AM ET
    $GMAB
    $MRUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MRUS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Genmab A/S bought $79,098,068 worth of shares (815,444 units at $97.00) (SEC Form 4)

    4 - Merus N.V. (0001651311) (Issuer)

    12/29/25 5:16:48 PM ET
    $MRUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Genmab A/S bought $27,008,777 worth of shares (278,441 units at $97.00) (SEC Form 4)

    4 - Merus N.V. (0001651311) (Issuer)

    12/22/25 5:15:45 PM ET
    $MRUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Genmab A/S bought $26,340,059 worth of shares (271,547 units at $97.00) (SEC Form 4)

    4 - Merus N.V. (0001651311) (Issuer)

    12/18/25 5:54:51 PM ET
    $MRUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MRUS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Barclays initiated coverage on Merus with a new price target

    Barclays initiated coverage of Merus with a rating of Overweight and set a new price target of $112.00

    9/17/25 8:02:58 AM ET
    $MRUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alliance Global Partners initiated coverage on Merus with a new price target

    Alliance Global Partners initiated coverage of Merus with a rating of Buy and set a new price target of $90.00

    8/25/25 7:58:18 AM ET
    $MRUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Piper Sandler initiated coverage on Merus with a new price target

    Piper Sandler initiated coverage of Merus with a rating of Overweight and set a new price target of $84.00

    2/13/25 8:09:56 AM ET
    $MRUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MRUS
    SEC Filings

    View All

    SEC Form 15-12G filed by Merus N.V.

    15-12G - Merus N.V. (0001651311) (Filer)

    1/9/26 6:15:56 AM ET
    $MRUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13D/A filed by Merus N.V.

    SCHEDULE 13D/A - Merus N.V. (0001651311) (Subject)

    12/30/25 5:24:40 PM ET
    $MRUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form 25-NSE/A filed by Merus N.V.

    25-NSE/A - Merus N.V. (0001651311) (Subject)

    12/30/25 9:04:23 AM ET
    $MRUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MRUS
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    December 6, 2024 - FDA Roundup: December 6, 2024

    For Immediate Release: December 06, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:On Thursday, the FDA published the draft guidance, “Expedited Program for Serious Conditions — Accelerated Approval of Drugs and Biologics,” which proposes updates to certain agency policies and procedures regarding accelerated approval. Topics addressed by this

    12/6/24 3:09:02 PM ET
    $MRUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MRUS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Genmab A/S bought $79,098,068 worth of shares (815,444 units at $97.00) (SEC Form 4)

    4 - Merus N.V. (0001651311) (Issuer)

    12/29/25 5:16:48 PM ET
    $MRUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Genmab A/S bought $27,008,777 worth of shares (278,441 units at $97.00) (SEC Form 4)

    4 - Merus N.V. (0001651311) (Issuer)

    12/22/25 5:15:45 PM ET
    $MRUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Genmab A/S bought $26,340,059 worth of shares (271,547 units at $97.00) (SEC Form 4)

    4 - Merus N.V. (0001651311) (Issuer)

    12/18/25 5:54:51 PM ET
    $MRUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MRUS
    Leadership Updates

    Live Leadership Updates

    View All

    Merus Appoints Fabian Zohren M.D., Ph.D., as Chief Medical Officer

    UTRECHT, The Netherlands and CAMBRIDGE, Mass., July 01, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced the appointment of Fabian Zohren M.D., PhD as Chief Medical Officer (CMO) effective July 1, 2024. Andrew Joe, M.D. will step down from the CMO role and continue to serve as a Consultant for the next three months. In addition, effective July 1, Hui Liu, Ph.D., EVP, Chief Business Officer & Head of Merus U.S. is leaving Merus. The Company has initiated a search to find a replacement to head the business development f

    7/1/24 8:00:00 AM ET
    $MRUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Merus Appoints Life Sciences Strategic and Financial Industry Veteran Greg Perry as Chief Financial Officer

    UTRECHT, The Netherlands and CAMBRIDGE, Mass., June 15, 2023 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced the appointment of Greg Perry as the Company's Chief Financial Officer (CFO). Additionally, Greg has been designated as the Company's principal financial officer, succeeding Bill Lundberg, M.D., in such role. In connection with his appointment as the Company's Chief Financial Officer, on June 14, 2023, Greg resigned from the Company's Board of Directors. "I am excited to welcome Greg as our CFO and look forward to drawing from his broad biotech e

    6/15/23 7:47:06 AM ET
    $MRUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Merus Appoints Shannon Campbell as Chief Commercial Officer and Regains Worldwide Rights to MCLA-145

    UTRECHT, The Netherlands and CAMBRIDGE, Mass., Jan. 25, 2022 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS) ("Merus", "the Company", "we", or "our"), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced the appointment of Shannon Campbell as Executive Vice President & Chief Commercial Officer. Ms. Campbell is an accomplished healthcare leader with demonstrated success leading commercial businesses across a range of specialty markets, including oncology. "Shannon will be instrumental in advancing Merus' mission to become a commercial-stage company, further advancing the strategy for our lead clinical progr

    1/25/22 4:30:00 PM ET
    $INCY
    $MRUS
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care
    Biotechnology: Pharmaceutical Preparations

    $MRUS
    Financials

    Live finance-specific insights

    View All

    Genmab to Acquire Merus, Expanding Late-Stage Pipeline and Accelerating into a Wholly Owned Model

    Company Announcement Genmab to acquire Merus for USD 97.00 per share in an all-cash transaction representing a transaction value of approximately USD 8.0 billion Proposed acquisition adds petosemtamab, a late-stage asset with two Breakthrough Therapy Designations, to Genmab's portfolio Transaction anticipated to be accretive to EBITDA by end of 2029 Genmab to host a conference call today at 1:00 PM CEST / 12:00 PM BST / 7:00 AM EDT Genmab A/S (NASDAQ: GMAB) and Merus N.V. (NASDAQ: MRUS) announced today that they have entered into a transaction agreement pursuant to which Genmab intends to acquire all the shares of Merus, a clinical-stage biotechnology company with its late-st

    9/29/25 1:14:00 AM ET
    $GMAB
    $MRUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Genmab to Acquire Merus, Expanding Late-Stage Pipeline and Accelerating into a Wholly Owned Model

    Company Announcement Genmab to acquire Merus for USD 97.00 per share in an all-cash transaction representing a transaction value of approximately USD 8.0 billionProposed acquisition adds petosemtamab, a late-stage asset with two Breakthrough Therapy Designations, to Genmab's portfolio Transaction anticipated to be accretive to EBITDA by end of 2029 Genmab to host a conference call today at 1:00 PM CEST / 12:00 PM BST / 7:00 AM EDT COPENHAGEN, Denmark; UTRECHT, The Netherlands; September 29, 2025, – Genmab A/S (NASDAQ: GMAB) and Merus N.V. (NASDAQ: MRUS) announced today that they have entered into a transaction agreement pursuant to which Genmab intends to acquire all the shares of Merus,

    9/29/25 1:08:26 AM ET
    $GMAB
    $MRUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Merus' Petosemtamab with Pembrolizumab Interim Data Demonstrates Robust Efficacy and Durability in 1L PD-L1+ r/m HNSCC

    -  63% response rate observed among 43 evaluable patients -  79% overall survival rate at 12-months; 9 months median progression-free survival -  Conference Call on Thursday, May 22 at 5:30 p.m. ET UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 22, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS) (Merus, the Company, we, or our), an oncology company developing innovative, full-length multispecific antibodies and antibody drug conjugates (Biclonics®, Triclonics® and ADClonics®), today announced interim clinical data as of a February 27, 2025 data cutoff from the ongoing phase 2 trial of the bispecific antibody petosemtamab in combination with pembrolizumab. These data will be

    5/22/25 5:30:00 PM ET
    $MRUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MRUS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Merus N.V.

    SC 13G/A - Merus N.V. (0001651311) (Subject)

    11/14/24 4:05:20 PM ET
    $MRUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Merus N.V.

    SC 13G/A - Merus N.V. (0001651311) (Subject)

    11/14/24 1:34:01 PM ET
    $MRUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Merus N.V.

    SC 13G/A - Merus N.V. (0001651311) (Subject)

    11/14/24 8:54:46 AM ET
    $MRUS
    Biotechnology: Pharmaceutical Preparations
    Health Care